Tryp Therapeutics Inc.: Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor
La Jolla, California (Newsfile Corp. - February 11, 2021) - Tryp Therapeutics (CSE: TRYP) ( Tryp or the Company ) a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has executed an advisory agreement with Dr. Joel Castellanos, a noted chronic pain physician at UC San Diego Medical Center to join the company s Scientific Advisory Board. He will guide Tryp s clinical development of TRP-8802 for neuropathic pain indications. Dr. Castellanos is the lead author of, Chronic pain and psychedelics: a review and proposed mechanism of action , which was published online in
Medcolcanna Organics Inc. Is Granted THC Psychoactive Quota to Be Used in Magistral Formulations and Other Medicinal Applications
Medcolcanna ,
MCCN or the
Company ), a Canadian integrated medical cannabis company with operations in Colombia, is pleased to announce it has been granted a Psychoactive Quota for the production of THC Derivates by the Ministry of Health and Social Protection in Colombia. This comes as the result of Medcolcanna s ability to meet regulatory requirements and the Company s commitment to provide access to cannabis based medication to patients in Colombia.
Following the November 2020 INVIMA certification of MCCN s laboratory under its Good Elaboration Practices for Magistral Preparations with Cannabis (GEP) program, authorizing the Company to manufacture high- and low-THC magistral preparations domestically, the grant of this latest THC Quota positions the Company as one of the few cannabis companies in the country with a certified lab for finished me
Press release content from Business Wire. The AP news staff was not involved in its creation.
CURE Pharmaceutical Announces Promotions and Additions to Board of Directors
February 11, 2021 GMT
OXNARD, Calif. (BUSINESS WIRE) Feb 11, 2021
CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of pharmaceutical technology, wellness products and drug delivery, announced today updates and additions to its Board of Directors.
ADVERTISEMENT
After a dedicated run as Chairman of the Board, William Yuan is stepping down and will continue to serve the Company as an advisor and Chairman Emeritus. Rubén José King-Shaw Jr, a highly qualified and respected member of the Board, has been selected to step into that role. Mr. King-Shaw brings with him three decades of executive leadership experience in the healthcare technology and private equity sectors. He recently served on the board of Atlanta-based Cotiviti Holdings, Inc. an
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal .
Myovant Sciences, Inc.February 11, 2021 GMT
ORGOVYX™ (relugolix) approved by the
U.S. Food and Drug Administration (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer; ORGOVYX launched in the U.S. in early January 2021
Announced collaboration with Pfizer in December 2020 to jointly develop and commercialize relugolix in oncology and relugolix combination tablet in women’s health in the U.S. and Canada